Lundbeck
HLUN-B.CO
#2796
Rank
NZ$10.87 B
Marketcap
NZ$10.96
Share price
-2.06%
Change (1 day)
5.60%
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

Earnings for Lundbeck (HLUN-B.CO)

Earnings in 2026 (TTM): NZ$1.45 Billion

According to Lundbeck's latest financial reports the company's current earnings are NZ$4.00 Billion. In 2025 the company made an earning of NZ$1.28 Billion, an increase over its 2024 earnings that were of NZ$0.93 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Lundbeck from 2009 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.45 B13.83%
2025 NZ$1.28 B37.43%
2024 NZ$0.93 B25.74%
2023 NZ$0.74 B21.77%
2022 NZ$0.60 B31.57%
2021 NZ$0.46 B-4.61%
2020 NZ$0.48 B-45.06%
2019 NZ$0.88 B-34.04%
2018 NZ$1.33 B12.83%
2017 NZ$1.18 B93.99%
2016 NZ$0.61 B-137.28%
2015 -NZ$1.64 Billion-1246.24%
2014 NZ$0.14 B-72.36%
2013 NZ$0.51 B4.38%
2012 NZ$0.49 B-55.18%
2011 NZ$1.10 B5.65%
2010 NZ$1.04 B-5.9%
2009 NZ$1.11 B